Adial Pharmaceuticals, Inc. (ADIL)

1.9000 -0.0300 (-1.55%) At close: 04:00PM EDT

Adial Pharmaceuticals, Inc.

1180 Seminole Trail
Suite 495
Charlottesville, VA 22901
United States
434 422 9800
https://www.adialpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 4

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Cary John Claiborne MBA	CEO, President & Director	728.31k	N/A	1961
Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D.	Founder & Chief Medical Officer	435k	N/A	1960
Mr. Joseph A. M. Truluck M.B.A., MBA	CFO, Treasurer & Secretary	358.49k	N/A	1978
Mr. Tony Goodman	COO & Director	33k	N/A	1964
Mr. John R. Martin J.D.	Chief Legal Officer	N/A	N/A	N/A
Ms. Catherine Fratila	Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Corporate governance

Adial Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.